Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma

Park, Hye Kyong; Lee, Sang Soo; Im, Chang Bin; Im, Chan Young; Cha, Ra Ri; Kim, Wan Soo; Cho, Hyun Chin; Lee, Jae Min; Kim, Hyun Jin; Kim, Tae Hyo; Jung, Woon Tae; Lee, Ok-Jae

doi:10.1186/s12885-019-6040-3

Cited by 15 publications

(7 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data were initially extracted from 15 selected studies[ 18 , 20 , 21 , 22 - 35 ] which provided information from a total of 12674 participants ( ). Preliminary analysis of the studies showed that these studies combined genotype data even with their primary focus on G3.…”

Section: Resultsmentioning

confidence: 99%

Risk factors for hepatocellular carcinoma associated with hepatitis C genotype 3 infection: A systematic review

Farooq,

James,

Abbott

et al. 2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

BACKGROUND Hepatitis C virus (HCV) is a blood-borne virus which globally affects around 79 million people and is associated with high morbidity and mortality. Chronic infection leads to cirrhosis in a large proportion of patients and often causes hepatocellular carcinoma (HCC) in people with cirrhosis. Of the 6 HCV genotypes (G1-G6), genotype-3 accounts for 17.9% of infections. HCV genotype-3 responds least well to directly-acting antivirals and patients with genotype-3 infection are at increased risk of HCC even if they do not have cirrhosis. AIM To systematically review and critically appraise all risk factors for HCC secondary to HCV-G3 in all settings. Consequently, we studied possible risk factors for HCC due to HCV-G3 in the literature from 1946 to 2023. METHODS This systematic review aimed to synthesise existing and published studies of risk factors for HCC secondary to HCV genotype-3 and evaluate their strengths and limitations. We searched Web of Science, Medline, EMBASE, and CENTRAL for publications reporting risk factors for HCC due to HCV genotype-3 in all settings, 1946-2023. RESULTS Four thousand one hundred and forty-four records were identified from the four databases with 260 records removed as duplicates. Three thousand eight hundred and eighty-four records were screened with 3514 excluded. Three hundred and seventy-one full-texts were assessed for eligibility with seven studies included for analysis. Of the seven studies, three studies were retrospective case-control trials, two retrospective cohort studies, one a prospective cohort study and one a cross-sectional study design. All were based in hospital settings with four in Pakistan, two in South Korea and one in the United States. The total number of participants were 9621 of which 167 developed HCC (1.7%). All seven studies found cirrhosis to be a risk factor for HCC secondary to HCV genotype-3 followed by higher age (five-studies), with two studies each showing male sex, high alpha feto-protein, directly-acting antivirals treatment and achievement of sustained virologic response as risk factors for developing HCC. CONCLUSION Although, studies have shown that HCV genotype-3 infection is an independent risk factor for end-stage liver disease, HCC, and liver-related death, there is a lack of evidence for specific risk factors for HCC secondary to HCV genotype-3. Only cirrhosis and age have demonstrated an association; however, the number of studies is very small, and more research is required to investigate risk factors for HCC secondary to HCV genotype-3.

show abstract

Section: Resultsmentioning

confidence: 99%

Risk factors for hepatocellular carcinoma associated with hepatitis C genotype 3 infection: A systematic review

Farooq,

James,

Abbott

et al. 2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

“…However, it is unclear what causes HCV genotype 3 to behave aggressively. However, the poor prognosis associated with HCV genotype 3 infection may also be attributed to hepatic steatosis, rapid fibrosis and insulin resistance [50]. Due to the non-availability of the genotype 3 virus stock, we utilized HCV-JFH1 (genotype 2 a) as a model to validate our work in cell-culture studies.…”

Section: Discussionmentioning

confidence: 99%

LncRNA NEAT1 regulates HCV-induced Hepatocellular carcinoma by modulating the miR-9-BGH3 axis

Tripathi

Pal

Ghosh

et al. 2022

Journal of General Virology

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver diseases, such as fibrosis, cirrhosis and hepatocellular carcinoma (HCC). Several cellular entities, including paraspeckles and their related components, are involved in viral pathogenesis and cancer progression. NEAT1 lncRNA is a major component of paraspeckles that has been linked to several malignancies. In this study, analysis of the Cancer Genome Atlas (TCGA) database and validation in HCV-induced HCC tissue and serum samples showed significantly high expression of NEAT1 in patients with liver cancer. Moreover, we found that NEAT1 levels increased upon HCV infection. To further understand the mechanism of NEAT1-induced HCC progression, we selected one of its targets, miR-9–5 p, which regulates BGH3 mRNA levels. Interestingly, miR-9–5 p levels were downregulated upon HCV infection, whereas BGH3 levels were upregulated. Additionally, partial NEAT1 knockdown increased miR-9–5 p levels and decreased BGH3 levels, corroborating our initial results. BGH3 levels were also upregulated in HCV-induced HCC and TCGA tissue samples, which could be directly correlated with NEAT1 levels. As a known oncogene, BGH3 is directly linked to HCC progression mediated by NEAT1. We also found that NEAT1 levels remained upregulated in serum samples from patients treated with direct-acting antivirals (DAA), indicating that NEAT1 might be a molecular trigger that promotes HCC development. Collectively, these findings provide molecular insights into HCV-induced HCC progression via the NEAT1-miR-9-BGH3 axis.

show abstract

“…[ 5 ] In addition, other factors associated with poor survival include alcohol consumption, age, smoking status, diabetes mellitus (DM), disease duration, viral genotype, and co-infection with other hepatotoxic viruses. [ 5 6 7 8 9 ] Moreover, CHC infection is a major cause of mortality among patients with concurrent HIV infection. [ 10 ]…”

Section: Introductionmentioning

confidence: 99%

Predictors of survival among patients with chronic hepatitis C at a tertiary care center in Oman

Al-Shuaili,

Al-Busafi,

Al-Naamani

et al. 2023

Saudi Journal of Gastroenterology

View full text Add to dashboard Cite

Background: Chronic hepatitis C (CHC) is a leading cause of cirrhosis and hepatocellular carcinoma (HCC) worldwide. This study aimed to determine rates and predictors of survival among Omani patients with CHC at a tertiary hospital in Muscat, Oman. Methods: This ambidirectional cohort study included all CHC patients who presented to the Sultan Qaboos University Hospital between January 2009 and December 2017. Baseline demographic, clinical, laboratory, and radiological data were analyzed. Patients were followed-up until death or the endpoint of the study (April 2022) to determine survival and associations with other parameters. Results: A total of 702 CHC patients were included, of which 398 (56.7%) were under 50 years of age and 477 (67.9%) were male. Overall, 180 patients (25.6%) died by the study endpoint. The mean duration of follow-up was 93.3 ± 48.0 months. The 5-year survival rate was estimated to be 80.5%, while the 10-year survival was 73%. Sustained virological response and the absence of diabetes mellitus, chronic kidney disease, HCC, or other malignancies were associated with significantly better overall survival. The 3- and 5-year survival rate of patients with hepatitis C virus (HCV)-related HCC was 46.5% and 27.6%, respectively, with a median survival of 29.5 months. Co-infection with hepatitis B was associated with poor survival among this subgroup; conversely, early HCV screening and the presence of a single HCC lesion were associated with better overall survival. Conclusions: National policies for early CHC screening and rapid treatment are needed to improve survival rates in this population.

show abstract

Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma

Cited by 15 publications

References 49 publications

Risk factors for hepatocellular carcinoma associated with hepatitis C genotype 3 infection: A systematic review

Risk factors for hepatocellular carcinoma associated with hepatitis C genotype 3 infection: A systematic review

LncRNA NEAT1 regulates HCV-induced Hepatocellular carcinoma by modulating the miR-9-BGH3 axis

Predictors of survival among patients with chronic hepatitis C at a tertiary care center in Oman

Contact Info

Product

Resources

About